Abstract: A novel P-selectin ligand glycoprotein is disclosed, comprising the amino acid sequence set forth in SEQ ID NO:2 or by the amino acid sequence set forth in SEQ ID NO:4. DNA sequences encoding the P-selectin ligand protein are also disclosed, along with vectors, host cells, and methods of making the P-selectin ligand protein. Pharmaceutical compositions containing the P-selectin ligand protein and methods of treating inflammatory disease states characterized by P-selectin- and E-selectin-mediated intercellular adhesion are also disclosed.
Type:
Grant
Filed:
July 3, 2008
Date of Patent:
July 31, 2012
Assignee:
Genetics Institute, LLC
Inventors:
Glenn R. Larsen, Dianne S. Sako, Xiao-Jia Chang, Geertruida M. Veldman, Dale Cumming, Ravindra Kumar, Gray Shaw
Abstract: Novel human GIL-19/AE289 protein is disclosed which shows a high degree of homology to interleukin-10 (IL-10). Polynucleotides encoding such protein are also enclosed.
Type:
Grant
Filed:
December 1, 2008
Date of Patent:
November 1, 2011
Assignee:
Genetics Institute, LLC
Inventors:
Kenneth Jacobs, Lynette Fouser, Vikki Spaulding, Dejun Xuan
Abstract: Inhibitors of IL-22 are disclosed as well as pharmaceutical compositions and methods of using same. The inhibitors include IL-22 antibodies and are useful for treating inflammatory disorders.
Type:
Application
Filed:
May 23, 2011
Publication date:
October 27, 2011
Applicant:
Genetics Institute, LLC
Inventors:
Kenneth Jacobs, Debra D. Pittman, Lynette Fouser, Vikki Spaulding, Dejun Xuan
Abstract: Method of treating autoimmune conditions are disclosed comprising administering to a mammalian subject IL-12 or an IL-12 antagonist. In certain preferred embodiments the autoimmune condition is one which is promoted by an increase in levels of IFN-? or TNF-?. Suitable conditions for treatment include multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes melitis and autoimmune inflammatory eye disease.
Type:
Grant
Filed:
May 14, 2009
Date of Patent:
September 6, 2011
Assignee:
Genetics Institute, LLC
Inventors:
John Leonard, Samuel Goldman, Richard O'Hara, Jr.
Abstract: Polynucleotides encoding the MU-1 hematopoietin receptor superfamily chain and fragments thereof are disclosed. MU-1 proteins, antibodies (and fragments thereof) that specifically bind to MU-1 proteins (and fragments thereof), and methods for their production are also disclosed.
Abstract: The invention provides isolated nucleic acids molecules, designated GL50 nucleic acid molecules, which encode novel GL50 polypeptides. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing GL50 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a GL50 gene has been introduced or disrupted. The invention still further provides isolated GL50 polypeptides, fusion proteins, antigenic peptides and anti-GL50 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
Type:
Grant
Filed:
August 18, 2009
Date of Patent:
July 12, 2011
Assignee:
Genetics Institute, LLC
Inventors:
Vincent Ling, Kyriaki Dunussi-Joannopoulos
Abstract: The present invention relates to a new complex receptor polypeptide LSR (Lipolysis Stimulated Receptor), characterized by its functional activities, the cloning of the cDNAs complementary to the messenger RNAs encoding each of the subunits of the multimeric complex, vectors and transformed cells, methods of diagnosis and of selection of compounds which can be used as medicament for the prevention and/or treatment of pathologies and/or of pathogeneses such as obesity and anorexia, hyperlipidemias, atherosclerosis, diabetes, hypertension, and more generally the various pathologies associated with abnormalities in the metabolism of cytokines.
Type:
Application
Filed:
February 3, 2011
Publication date:
July 7, 2011
Applicants:
Serono Genetics Institute S.A., Institut National De La Sante Et De La Recherche Medicale (INSERM)
Inventors:
BERNARD BIHAIN, Lydie Bougueleret, Frances Yen-Potin
Abstract: The subject of the invention is the genomic sequence and the nucleotide sequences encoding polypeptides of Chlamydia trachomatis, such as cellular envelope polypeptides, which are secreted or specific, or which are involved in metabolism, in the replication process or in virulence, polypeptides encoded by such sequences, as well as vectors including the said sequences and cells or animals transformed with these vectors. The invention also relates to transcriptional gene products of the Chlamydia trachomatis genome, such as, for example, antisense and ribozyme molecules, which can be used to control growth of the microorganism. The invention also relates to methods of detecting these nucleic acids or polypeptides and kits for diagnosing Chlamydia trachomatis infection. The invention also relates to a method of selecting compounds capable of modulating bacterial infection and a method for the biosynthesis or biodegradation of molecules of interest using the said nucleotide sequences or the said polypeptides.
Type:
Application
Filed:
February 28, 2011
Publication date:
June 30, 2011
Applicant:
SERONO GENETICS INSTITUTE S.A.
Inventors:
Remy Griffais, Susan K. Hoiseth, Robert J. Zagursky, Benjamin J. Metcalf, Joel A. Peek, Banumathi Sankaran, Leah D. Fletcher
Abstract: A novel P-selectin ligand glycoprotein is disclosed, comprising the amino acid sequence set forth in SEQ ID NO:2 or by the amino acid sequence set forth in SEQ ID NO:4. DNA sequences encoding the P-selectin ligand protein are also disclosed, along with vectors, host cells, and methods of making the P-selectin ligand protein. Pharmaceutical compositions containing the P-selectin ligand protein and methods of treating inflammatory disease states characterized by P-selectin- and E-selectin-mediated intercellular adhesion are also disclosed.
Type:
Grant
Filed:
July 3, 2008
Date of Patent:
April 19, 2011
Assignee:
Genetics Institute, LLC
Inventors:
Glenn R. Larsen, Dianne S. Sako, Xiao-Jia Chang, Geertruida M. Veldman, Dale Cumming, Ravindra Kumar, Gray Shaw
Abstract: The present invention relates to antibodies specific for a receptor termed the Lipolysis Stimulated Receptor (LSR). Compositions comprising the antibodies are also provided.
Type:
Grant
Filed:
September 27, 2007
Date of Patent:
April 5, 2011
Assignees:
Serono Genetics Institute S.A., Institut National de la Sante Et de la Recherche Medicale (Inserm)
Inventors:
Bernard Bihain, Lydie Bougueleret, Frances Yen-Potin
Abstract: The subject of the invention is the genomic sequence and the nucleotide sequences encoding polypeptides of Chlamydia trachomatis, such as cellular envelope polypeptides, which are secreted or specific, or which are involved in metabolism, in the replication process or in virulence, polypeptides encoded by such sequences, as well as vectors including the said sequences and cells or animals transformed with these vectors. The invention also relates to transcriptional gene products of the Chlamydia trachomatis genome, such as, for example, antisense and ribozyme molecules, which can be used to control growth of the microorganism. The invention also relates to methods of detecting these nucleic acids or polypeptides and kits for diagnosing Chlamydia trachomatis infection. The invention also relates to a method of selecting compounds capable of modulating bacterial infection and a method for the biosynthesis or biodegradation of molecules of interest using the said nucleotide sequences or the said polypeptides.
Type:
Grant
Filed:
June 25, 2009
Date of Patent:
March 22, 2011
Assignee:
Serono Genetics Institute S.A.
Inventors:
Rémy Griffais, Susan K. Hoiseth, Robert J. Zagursky, Benjamin J. Metcalf, Joel A. Peek, Banumathi Sankaran, Leah D. Fletcher
Abstract: Methods and compositions are provided for the treatment of articular cartilage defects and disease involving the combination of tissue, such as osteochondral grafts, with active growth factor. The active growth factor is preferably a composition containing at least one bone morphogenetic protein and a suitable carrier. The method results in the regeneration and/or functional repair of articular cartilage tissue.
Type:
Grant
Filed:
December 17, 2008
Date of Patent:
November 30, 2010
Assignee:
Genetics Institute, LLC
Inventors:
Renwen Zhang, Diane Peluso, Elisabeth Morris
Abstract: The invention concerns the genomic sequence of the FLAP gene. The invention also concerns biallelic markers of a FLAP gene and the association established between these markers and diseases involving the leukotriene pathway such as asthma. The invention provides means to determine the predisposition of individuals to diseases involving the leukotriene pathway as well as means for the diagnosis of such diseases and for the prognosis/detection of an eventual treatment response to agents acting on the leukotriene pathway.
Type:
Grant
Filed:
December 30, 2008
Date of Patent:
November 23, 2010
Assignee:
Serono Genetics Institute S.A.
Inventors:
Marta Blumenfeld, Ilya Chumakov, Lydie Bougueleret
Abstract: Methods are provided for purification of Factor VIII polypeptides by affinity chromatography and ion exchange chromatography, in which the eluate from the affinity column is diluted with a solution comprising higher salt concentration, or lower non-polar agent concentration than that of the elution solution, prior to passing the diluted solution through the ion exchange column. The affinity matrix may comprise a monoclonal antibody or a peptide ligand. The methods result in improved purification without significant yield loss.
Type:
Grant
Filed:
January 26, 2005
Date of Patent:
October 26, 2010
Assignee:
Genetics Institute, LLC.
Inventors:
James Booth, Suresh Vunnum, Brian D. Kelley
Abstract: The invention provides isolated nucleic acids molecules, designated PD-L2 nucleic acid molecules, which encode novel B7-related molecules which are ligands for PD-1. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PD-L2 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PD-L2 gene has been introduced or disrupted. The invention further provides isolated PD-L2 polypeptides, fusion proteins, antigenic peptides and anti-PD-L2 antibodies. The invention still further provides methods for promoting or inhibiting the interaction between PD-L2 and PD-1. Diagnostic and treatment methods utilizing compositions of the invention are also provided.
Type:
Grant
Filed:
June 20, 2007
Date of Patent:
May 4, 2010
Assignees:
Dana-Farber Cancer Institute, Inc., Genetics Institute, LLC
Inventors:
Gordon J. Freeman, Irene Chernova, Tatyana Chernova, Nelly Malenkovich, Clive R. Wood
Abstract: Polynucleotides encoding the MU-1 hematopoietin receptor superfamily chain and fragments thereof are disclosed. MU-1 proteins and methods for their production are also disclosed.
Abstract: Polynucleotides encoding the IL-13 receptor and fragments thereof are disclosed. IL-13 receptor proteins, methods for their production, inhibitors of binding of IL-13 and its receptor and methods for their identification are also disclosed. Methods of medical treatment using such molecules and antagonists of the IL-13/IL-13R interaction are also provided.
Type:
Application
Filed:
March 20, 2009
Publication date:
April 8, 2010
Applicants:
GENETICS INSTITUTE, LLC, THE JOHNS HOPKINS UNIVERSITY
Inventors:
Mary Collins, Debra Donaldson, Lori Fitz, Tamlyn Neben, Matthew J. Whitters, Clive Wood, Marsha Wills-Karp
Abstract: The present invention relates to a methods for producing recombinant heterodimeric BMP proteins useful in the field of treating bone defects, healing bone injury and in wound healing in general. The invention also relates to the recombinant heterodimers and compositions containing them.
Abstract: Polynucleotides encoding the IL-13 receptor and fragments thereof are disclosed. IL-13 receptor proteins, methods for their production, inhibitors of binding of IL-13 and its receptor and methods for their identification are also disclosed.
Type:
Grant
Filed:
February 27, 2006
Date of Patent:
March 9, 2010
Assignee:
Genetics Institute, LLC
Inventors:
Mary Collins, Debra Donaldson, Lori Fitz, Tamlyn Neben, Matthew Whitters, Clive Wood
Abstract: The present invention relates to the field of obesity research. Obesity is a public health problem that is serious and widespread. The application is related to OBG3 polypepide fragments and compositions comprising these fragments. It also discloses methods of reducing free fatty acid levels with the polypeptide fragments of the invention.
Type:
Grant
Filed:
May 23, 2008
Date of Patent:
March 2, 2010
Assignee:
Serono Genetics Institute S.A.
Inventors:
Joachim Fruebis, Mary Ruth Erickson, Frances Yen-Potin, Bernard Bihain